APA (7th ed.) Citation

Monzon, J. G., Karachiwala, H., Walker, J., Goel, R., Wheatley-Price, P., Asmis, T. R., . . . Vickers, M. M. (2026). Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709]. European Journal of Cancer, 240, N.PAG. https://doi.org/10.1016/j.ejca.2026.116738

Chicago Style (17th ed.) Citation

Monzon, Jose G., Hatim Karachiwala, John Walker, Rakesh Goel, Paul Wheatley-Price, Timothy R. Asmis, Vishal Navani, Patricia A. Tang, and Michael M. Vickers. "Corrigendum to "A Non-randomized Phase 2 Trial of Pembrolizumab in Untreated Patients with Carcinoma of Unknown Primary Site" [Eur J Cancer (2026) 239 116709]." European Journal of Cancer 240 (2026): N.PAG. https://doi.org/10.1016/j.ejca.2026.116738.

MLA (9th ed.) Citation

Monzon, Jose G., et al. "Corrigendum to "A Non-randomized Phase 2 Trial of Pembrolizumab in Untreated Patients with Carcinoma of Unknown Primary Site" [Eur J Cancer (2026) 239 116709]." European Journal of Cancer, vol. 240, 2026, p. N.PAG, https://doi.org/10.1016/j.ejca.2026.116738.